IL157770A0 - Methods for treating stress disorders using glucocorticoid receptor-specific antagonists - Google Patents

Methods for treating stress disorders using glucocorticoid receptor-specific antagonists

Info

Publication number
IL157770A0
IL157770A0 IL15777002A IL15777002A IL157770A0 IL 157770 A0 IL157770 A0 IL 157770A0 IL 15777002 A IL15777002 A IL 15777002A IL 15777002 A IL15777002 A IL 15777002A IL 157770 A0 IL157770 A0 IL 157770A0
Authority
IL
Israel
Prior art keywords
methods
glucocorticoid receptor
stress disorders
specific antagonists
treating stress
Prior art date
Application number
IL15777002A
Other languages
English (en)
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of IL157770A0 publication Critical patent/IL157770A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL15777002A 2001-03-23 2002-03-19 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists IL157770A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27852301P 2001-03-23 2001-03-23
PCT/US2002/008622 WO2002076390A2 (fr) 2001-03-23 2002-03-19 Methodes de traitement des troubles du stress au moyen d'antagonistes specifiques du recepteur des glucocorticoides

Publications (1)

Publication Number Publication Date
IL157770A0 true IL157770A0 (en) 2004-03-28

Family

ID=23065304

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15777002A IL157770A0 (en) 2001-03-23 2002-03-19 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
IL157770A IL157770A (en) 2001-03-23 2003-09-04 Use of a glucocorticoid receptor antagonist in the manufacture of a medicament for ameliorating the symptoms of a stress disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157770A IL157770A (en) 2001-03-23 2003-09-04 Use of a glucocorticoid receptor antagonist in the manufacture of a medicament for ameliorating the symptoms of a stress disorder

Country Status (16)

Country Link
US (1) US6964953B2 (fr)
EP (1) EP1370268B1 (fr)
JP (2) JP2004525135A (fr)
KR (1) KR100895662B1 (fr)
CN (2) CN1820756A (fr)
AU (1) AU2002255845B2 (fr)
CA (1) CA2440605C (fr)
DE (1) DE60232956D1 (fr)
DK (1) DK1370268T3 (fr)
ES (1) ES2326364T3 (fr)
IL (2) IL157770A0 (fr)
NO (1) NO334745B1 (fr)
NZ (1) NZ528147A (fr)
PT (1) PT1370268E (fr)
WO (1) WO2002076390A2 (fr)
ZA (1) ZA200307066B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
CN1527713A (zh) * 2001-05-04 2004-09-08 �Ƹ��� 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法
BR0213466A (pt) * 2001-10-26 2004-11-09 Akzo Nobel Nv Uso de (11beta,17beta)-11-(1,3- benzodioxol-s-il)-17-hidróxi-17-(1-propinil) estra-4,9-dien-3-ona, preparação farmacêutica, e, método para o tratamento de um paciente sofrendo de distúrbio depressivo grave
EP1453495A2 (fr) 2001-11-23 2004-09-08 Akzo Nobel N.V. Traitement de troubles depressifs majeurs au moyen d'antagonistes de recepteurs des glucocorticoides
JP2007524616A (ja) * 2003-06-20 2007-08-30 ヴァイラル・ジェノミックス・インコーポレーテッド Ｈｉｖを処置するための組成物および方法
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
WO2005118810A1 (fr) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents et procedes pour le diagnostic de stress
WO2008137270A1 (fr) * 2007-05-04 2008-11-13 H. Lundbeck A/S Procédés de diagnostic et de suivi d'affections associées au npy y5
US8598149B2 (en) 2007-08-30 2013-12-03 Corcept Therapeutics, Inc. Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
US11103514B2 (en) * 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
EP3231421A1 (fr) * 2016-04-11 2017-10-18 Greenaltech, S.L. Utilisations d'un caroténoïde dans le traitement ou la prévention d'états induits par le stress
CN110475558A (zh) 2017-03-09 2019-11-19 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用
JP2022515528A (ja) * 2018-12-28 2022-02-18 パンダ コンサルティング エルエルシー 短時間作用型選択的糖質コルチコイド受容体モジュレーター

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1261165B (it) * 1993-01-25 1996-05-09 Polifarma Spa Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
DK1023074T3 (da) 1997-10-06 2006-11-06 Univ Leland Stanford Junior Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion
NZ334627A (en) * 1999-03-12 2002-07-26 Horticulture & Food Res Inst A therapeutic composition containing a therapeutic agent such as an anthelmintic and an antistress agent such as metyrapone or a nitric oxide promoter for increasing efficacy of therapeutic agents and animal growth
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EP1127882A1 (fr) * 2000-01-25 2001-08-29 Pfizer Products Inc. Composés tétrazoliques comme ligands du récepteur thyroid
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
IL157770A (en) 2010-11-30
WO2002076390A3 (fr) 2003-05-22
EP1370268A4 (fr) 2005-02-09
AU2002255845B2 (en) 2006-11-23
CA2440605C (fr) 2012-01-10
PT1370268E (pt) 2009-08-26
EP1370268B1 (fr) 2009-07-15
NO20034232L (no) 2003-11-21
DE60232956D1 (de) 2009-08-27
CN1820756A (zh) 2006-08-23
DK1370268T3 (da) 2009-09-14
JP2009102412A (ja) 2009-05-14
KR100895662B1 (ko) 2009-05-07
EP1370268A2 (fr) 2003-12-17
CN1556709A (zh) 2004-12-22
CA2440605A1 (fr) 2002-10-03
JP2004525135A (ja) 2004-08-19
US20020169152A1 (en) 2002-11-14
US6964953B2 (en) 2005-11-15
ZA200307066B (en) 2004-09-10
NO20034232D0 (no) 2003-09-23
NZ528147A (en) 2005-06-24
ES2326364T3 (es) 2009-10-08
WO2002076390A2 (fr) 2002-10-03
KR20030093266A (ko) 2003-12-06
NO334745B1 (no) 2014-05-19

Similar Documents

Publication Publication Date Title
IL157770A0 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
GB2384350B (en) Apparatus for credential authorisation
EP1683067A4 (fr) Procede permettant de depister et de traiter des patients presentant un risque de troubles medicaux
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
AU2003287045A1 (en) Cytokine antagonists for neurological and neuropsychiatric disorders
AU2003297761A1 (en) Methods for treating neurological language disorders
AU2003239489A8 (en) Method of treating dyslipidemic disorders
PL373626A1 (en) Treatment for central nervous system disorders
AU2003286611A8 (en) Cytomodulating peptides and methods for treating neurological disorders
AU2003216464A8 (en) Certification method for manufacturing process
EP1487471A4 (fr) Techniques de traitement de maladies auto-immunes et reactifs associes
HK1082393A1 (en) Toothbrush and method for producing the same
EP1476147A4 (fr) Methodes de traitement de troubles de la vue
EP1567198A4 (fr) Procedes et materiaux destines a traiter des troubles oculaires
EP1400603A4 (fr) Bague de chenille et son appareil de production
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
PL371740A1 (en) Method for the recovery of gold
EP1549343A4 (fr) Methode de traitement de la nephrite faisant intervenir des anticorps anti-pdgf-dd
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
EP1359915A4 (fr) Antagonistes des recepteurs de l'urotensine-ii
HUP0400129A3 (en) Method for producing isocyanates
IL163993A0 (en) Method for treating cognitive disorders
EP1695061A4 (fr) Procede de traitement de troubles neurologiques
PL370367A1 (en) Ccr-3 receptor antagonists v